TREATMENT OF WALDENSTROMS MACROGLOBULINEMIA WITH VERY-LOW DOSES OF ALPHA-INTERFERON

被引：13

作者：

LEGOUFFE, E ^{[1
]}

ROSSI, JF ^{[1
]}

LAPORTE, JP ^{[1
]}

ISNARD, F ^{[1
]}

OZIOL, E ^{[1
]}

FABBRO, M ^{[1
]}

JANBON, C ^{[1
]}

JOURDAN, J ^{[1
]}

NAJMAN, A ^{[1
]}

机构：

[1] HOP LAPEYRONIE,SERV MALAD SANG,F-34295 MONTPELLIER 5,FRANCE

来源：

LEUKEMIA & LYMPHOMA | 1995年 / 19卷 / 3-4期

关键词：

WALDENSTROMS DISEASE; ALPHA INTERFERON;

D O I：

10.3109/10428199509107907

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Waldenstrom's macroglobulinemia (WM) is a differentiated B-cell malignancy which is usually less responsive to standard chemotherapy because of low-proliferating cells. Interferon alpha has been shown to possess a therapeutic action in numerous B-cell malignancies including the early stage of chronic lymphocytic leukemia, multiple myeloma, follicular lymphoma and hairy cell leukemia. Fourteen patients with progressive WM were included in a pilot study using very low dose of interferon alpha-2a (1 Million Units 3 times a week). The mean duration of treatment was 10.3 months (range 2-44). Six of 14 (42%) patients presented an increase in the hemoglobin level (greater than or equal to 0.9g/dL) and 4/14 (28%) had a substantial decrease of the monoclonal component (greater than or equal to 20% of reduction). Only two patients presented both types of response, while the others with an increase in the hemoglobin level had a slight decrease in the monoclonal component (MC) (1 patient), a stable MC (1 patient) or a slight increase of MC (1 patient). One additional patient had a 15% decrease of the MC with a stable hemoglobin level. Response was observed within 3 months with a median duration of 6 months. Treatment was stopped for 3 patients because of flu-like symptoms (2 patients), or thrombocytopenia (1 patient). Follow up was possible in 12 patients lasting up to a maximum of 30 months after discontinuing treatment, Seven patients died, including 4 with progressive disease, two of infection and one of cardiac failure. In the view of these results, very low dose of interferon alpha may constitute a new approach for treatment of some cases of WM.

引用

页码：337 / 342

页数：6

共 33 条

[1]

Krajny M., Pruzanski W., Waldenström's macroglobulinemia: review of 45 cases, Canadian Medical Association Journal, 114, pp. 899-905, (1976)

[2]

Quesada J.R., Reuben J.R., Manning J.T., Hersch E.M., Gutterman J.U., Alpha interferon for induction of remission in hairy cell leukemia, N. Engl. J. Med., 310, pp. 15-18, (1984)

[3]

Thompson J.A., Fefer A., Interferon in the treatment of hairy cell leukemia, Cancer, 59, pp. 605-1443, (1987)

[4]

Mandelli F., Avvisati G., Amadori S., Boccadoro M., Gernone A., Lauta V.M., Marmont F., Petrucci M.T., Tribalto M., Vegna M.L., Dammacco F., Pileri A., Maintenance treatment with recombinant interferon alfa-2b in patients with multiple myeloma responding to conventional induction Chemotherapy, N. Engl. J. Med., 322, pp. 1430-1443, (1990)

[5]

Ziegler-Heitbrock H.W.L., Schlag R., Flieger D., Thiel E., Favorable response of early stage B CLL patients to treatment with IFN-alpha2, Blood, 73, pp. 1426-1430, (1989)

[6]

O'Connell J., Colgan J.P., Oken M.M., Ritts R.E., Kay N.E., Itri L.M., Clinical trial of recombinant leukocyte A interferon as initial therapy for avorable histology non Hodgkin's lymphomas and chronic lymphocytic leukemia. An Eastern cooperative oncology group pilot study, Journal of Clinical Oncology, 4, pp. 128-136, (1986)

[7]

Solal-Celigny P., Lepage E., Brousse N., Reyes F., Haioun C., Leporrier M., Peuchmaur M., Bosly A., Parlier Y., Brice P., Coiffer B., Gisselbrecht C., Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma, N. Engl J. Med., 329, pp. 1608-1614, (1993)

[8]

Price C.G.A., Et al., interferon alfa-2b in the treatment of-follicular lymphoma: preliminary results of a trial in progress, Ann. Oncol., 2, pp. 141-145, (1991)

[9]

Smalley R.V., Andersen J.W., Hawkins M.J., Bhide V., O'Connell M.J., Oken M.M., Borden E.C., Interferon alfa combined with cytotoxic chemotherapy for patients with non Hodgkin's lymphoma, N. Engl. J. Med., 327, pp. 1336-1341, (1992)

[10]

McLaughlin P., Cabanillas F., Hagemeister F.B., Et al., CHOP-Bleo plus interferon fdor stage IV low-grade lymphoma, Ann. Oncol., 4, pp. 205-211, (1993)

← 1 2 3 4 →